Premium
Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin
Author(s) -
Cosgriff Thomas M.,
Black Marcus L.,
Stein William
Publication year - 1998
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199801)57:1<85::aid-ajh16>3.0.co;2-8
Subject(s) - medicine , refractory (planetary science) , thrombocytopenic purpura , splenectomy , platelet , chemotherapy , doxorubicin , gastroenterology , drug , surgery , pharmacology , spleen , physics , astrobiology
Idiopathic thrombocytopenic purpura (ITP) is refractory to initial treatment (steroids and splenectomy) in 25 to 30% of patients. These patients have a significant risk of fatal hemorrhage. Two patients with ITP refractory to multiple interventions and severe depression of platelet counts responded to treatment with liposomal doxorubicin with a return of platelet counts to normal. The drug is easily administered and was well tolerated. Use of this drug in refractory ITP merits further study. Am. J. Hematol. 57:85–86, 1998. © 1998 Wiley‐Liss, Inc.